Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12608
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIyngkaran, Pen
dc.contributor.authorMajoni, Wen
dc.contributor.authorCass, Alanen
dc.contributor.authorSanders, Prashanthanen
dc.contributor.authorRonco, Claudioen
dc.contributor.authorBrady, Sen
dc.contributor.authorKangaharan, Nen
dc.contributor.authorIlton, Men
dc.contributor.authorHare, David Len
dc.contributor.authorThomas, Merlin Cen
dc.date.accessioned2015-05-16T02:19:30Z-
dc.date.available2015-05-16T02:19:30Z-
dc.date.issued2014-12-24en
dc.identifier.citationHeart, Lung & Circulation 2014; 24(6): 536-43en
dc.identifier.govdoc25637942en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12608en
dc.description.abstractCongestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.en
dc.language.isoenen
dc.subject.otherGuidelinesen
dc.subject.otherHeart Failureen
dc.subject.otherIndigenous Australiansen
dc.subject.otherRemoteen
dc.subject.otherRuralen
dc.subject.otherTherapeuticsen
dc.titleNorthern Territory Perspectives on Heart Failure With Comorbidities - Understanding Trial Validity and Exploring Collaborative Opportunities to Broaden the Evidence Base.en
dc.typeJournal Articleen
dc.identifier.journaltitleHeart, Lung & Circulationen
dc.identifier.affiliationCentre for Heart Rhythm Disorders (CHRD), South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide and Royal Adelaide Hospital, Adelaide, Australiaen
dc.identifier.affiliationBaker IDI Heart and Diabetes Institute, Central Melbourne Victoria 3004, Australiaen
dc.identifier.affiliationRoyal Darwin Hospital, Flinders University, Darwin Private Hospital, Tiwi, NT 0811en
dc.identifier.affiliationRoyal Darwin Hospital, Department of Nephrology Division of Medicineen
dc.identifier.affiliationMenzies School of Health Research, Casuarina NT 0811en
dc.identifier.affiliationDepartment of Nephrology Dialysis & Transplantation, International Renal Research Institute (IRRIV) San Bortolo Hospital, Vicenza, Italyen
dc.identifier.affiliationAlice Springs Hospital, Alice Springs NT 0871en
dc.identifier.affiliationDivision of Medicine, Royal Darwin Hospital, Royal Darwin Hospital, Tiwi, NT 0810en
dc.identifier.affiliationRoyal Darwin Hospital, Royal Darwin Hospital, Tiwi, NT 0810en
dc.identifier.affiliationCoordinator, Cardiovascular Research, University of Melbourne; Director of Heart Failure Services, Austin Health, Vic 3084en
dc.identifier.doi10.1016/j.hlc.2014.12.007en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/25637942en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.